

# eInvest Better Future Fund (Managed Fund)

ASX:IMPQ  
MONTHLY REPORT OCTOBER 2021

	Month (%)	Quarter (%)	FYTD (%)	1 Year (%)	2 Year (%p.a)	Since Inception <sup>^</sup> (% p.a.)	Since Inception Cumulative <sup>^</sup> (%)
eInvest Better Future Fund (Managed Fund)	-0.9	4.5	4.4	33.9	19.2	19.1	53.3
S&P/ASX Small Ordinaries Accum. Index	0.9	3.7	4.4	31.0	13.1	11.6	30.8
<b>Value Added (Detracted)</b>	<b>-1.8</b>	<b>0.8</b>	<b>0.0</b>	<b>2.9</b>	<b>6.1</b>	<b>7.5</b>	<b>22.5</b>

<sup>^</sup>Inception date was 23 May 2019. Performance shown above are net of fees. Fund returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

## Overview

- IMPQ was down 0.9% net of fees in October, underperforming the benchmark return by 1.8%.
- It is over two years since the inception of the Fund. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest with a focus on shaping a better future. Since inception in May 2019, the Fund has delivered a 19.1% p.a. return net of fees, outperforming the benchmark by 7.5% p.a.
- Positive contributors this month included Janison Education (+18.1%), Imricor Medical Systems (+17.4%) and 3P Learning (+16.2%).
- Negative contributors this month included Control Bionics (-27.8%), Pental (-19.6%) and Smartgroup (-15.6%).

## eInvest Better Future Fund (Managed Fund)

The aim of IMPQ is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or conduct business in industries which have favourable characteristics having regard to ESG considerations. IMPQ seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index.

### Portfolio Manager

Damian Cottier

### IMPQ FUM

\$33 million

### Distribution Frequency

Annually (if any)

### Management Cost


0.99% (incl of GST and RITC)

### Inception Date

23 May 2019

+ performance fee

## Portfolio's contribution to UN Sustainable Development Goals



Total Contribution: 72.26%

(equal to 58.66% social impact contribution and 13.6% environmental impact contribution)

Source: Data provided by the Sustainable Platform 31 August 2021; based on company revenues

**eInvest Better Future Fund (ASX:IMPQ) – Monthly Report October 2021**

## Better Future Highlight

Last month, we established a position in 3P Learning ("3PL") in the portfolio. 3PL is best known for its Mathletics product that is used by schools in Australia and globally to encourage primary school students to develop their maths skills in a way that is more like play than traditional techniques.


3PL recently merged with Blake eLearning which owns the Reading Eggs product which takes a similar "play" approach to teaching children to read.

The company has been re-energised following the merger with a number of people who were involved in Mathletics when it was a start-up and who went on to develop Reading Eggs joining 3PL.

Historically, Mathletics' key focus has been on providing the product to schools, while the key focus of the Reading Eggs team was on direct-to-consumer markets.

Moving forward, the company is looking to revitalise the Mathletics program and focus the merged company's increased resources on both the school and direct-to-consumer markets globally for Reading Eggs and Mathletics. This is likely to be beneficial for both students globally and 3PL's prospects.

## Sector Active Exposure vs Index



## Fund Review

IMPQ was down 0.9% net of fees in October, underperforming the benchmark return by 1.8%.

It is over two years since the inception of the Fund. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest with a focus on shaping a better future. Since its inception in May 2019, the Fund has delivered a 19.1% p.a. return net of fees, outperforming the benchmark by 7.5% p.a.

Positive contributors this month included Janison Education (+18.1%), Imricor Medical Systems (+17.4%) and 3P Learning (+16.2%).

Negative contributors this month included Control Bionics (-27.8%), Pental (-19.6%) and Smartgroup (-15.6%).

Janison Education provided a positive AGM trading update and announced a small "bolt on" acquisition of the Quality Assessment Tasks ("QAT") business. The QAT is an Australian market leader in the development of school assessments for Year 11 and 12 subjects. Janison will integrate the business including assessments, question bank and network of question developers and reviewers into Janison's existing business and exam platform.

Imricor Medical Systems announced that the company had signed the Semmelweis Heart and Vascular Centre in Budapest, Hungary as a new client. Cardiac catheter ablation procedures using Imricor's products are expected to commence this year. The leader of the program that will be using the products is Dr. Bela Merkely who received the prestigious Szechenyi Prize this year, honouring the greatest scientists in Hungary alive today.

Smartgroup which announced it had received a non-binding indicative proposal last month, announced that the potential acquirer of the business no longer intended to proceed with the offer at the initially indicated price. The board rejected a lower proposed price given the outlook for the business and reaffirmed that the company was trading in line with market expectations.

Control Bionics provided a slightly softer than expected quarterly update due to the ongoing COVID disruptions in both Australia and the US. In our view the company's products that assist people with conditions such as MMD and spinal injuries to communicate are well positioned once these headwinds abate.

During the month, we established a small position in Impedimed as part of a capital raising. The funds were raised to support growth after the company announced the results of a medical trial of the company's bioimpedance spectroscopy (BIS) product that was conducted in 1,200 patients across 10 trial sites in the US and Australia. The study demonstrated that early detection of cancer related lymphoedema using the company's product resulted in a significantly lower rate of progression to chronic lymphoedema than patients using the existing standard of care. The use of the product will lead to better outcomes for breast cancer patients at risk of lymphoedema.

At month-end the portfolio held 50 stocks and cash was 8.3%.

At October end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Fund was 7.2 which is 26% higher than the benchmark ESGE Score of 5.7.

## Contact Us

📍 Level 27, 88 Phillip Street Sydney NSW 2000

☎ 1300 088 660

✉ hello@invest.com.au

🌐 www.invest.com.au

The Responsible Entity is Perennial Investment Management Limited ABN 13 108 747 637, AFSL: 275101. The Investment Manager is Perennial Value Management Limited ABN 22 090 879 904 AFSL: 247293. This report has been prepared by ETF Investments Australia Pty Ltd trading as invest Australia ('invest') ABN: 88 618 802 912, as the corporate authorised representative of Perennial Investment Management Limited. This report is for information purposes only. Accordingly, reliance should not be placed on this information as the basis for making an investment, financial or other decision. This information does not take into account your investment objectives, particular needs or financial situation. While every effort has been made to ensure the information is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. The current relevant product disclosure statement can be found at [www.invest.com.au/IMPQ](http://www.invest.com.au/IMPQ) and you can find the IMPQ TMD at [www.invest.com.au/targetmarketdeterminations/](http://www.invest.com.au/targetmarketdeterminations/)

**invest Better Future Fund (ASX:IMPQ) – Monthly Report October 2021**

## ESG Activity

Our ESG activity during the month included:

- Kathmandu announced the appointment of Abby Foote as a director which is pleasing after our past engagement with the company on gender diversity. The company also recently appointed Brooke Farris as the CEO of the company's key Rip Curl business.
- We met with 3P Learning to discuss the company's approach to governance, gender diversity, initiatives to provide the company's products to disadvantaged students and ESG reporting post the Blake eLearning merger.
- We met with Opthea to discuss the company's plans on ESG reporting and remuneration structures for directors.
- We met with Control Bionics to discuss governance and remuneration structures, ESG reporting and gender diversity.
- We met with Bendigo Bank to discuss the company's carbon targets, lending practices and their general approach to ESG.
- We met with Integral Diagnostics to suggest improvements to the company's long term incentive structures to include an additional return on invested capital metric.

## Top 5 Portfolio Positions

	IMPQ	Index
Calix Limited	3.5%	0.0%
Janison Education Group Ltd	3.4%	0.0%
Spark New Zealand Ltd	3.4%	0.3%
Meridian Energy Ltd	3.2%	0.0%
Integral Diagnostics Ltd	3.1%	0.3%



## Better Future and ESG Team

Damian Cottier – Portfolio Manager

Emilie O'Neill – Co-Head ESG & Equities Analyst